25174-38-3Relevant articles and documents
BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 274, (2017/08/01)
The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
Discovery and SAR of new benzazepines as potent and selective 5-HT 2C receptor agonists for the treatment of obesity
Smith, Brian M.,Smith, Jeffrey M.,Tsai, James H.,Schultz, Jeffrey A.,Gilson, Charles A.,Estrada, Scott A.,Chen, Rita R.,Park, Douglas M.,Prieto, Emily B.,Gallardo, Charlemagne S.,Sengupta, Dipanjan,Thomsen, William J.,Saldana, Hazel R.,Whelan, Kevin T.,Menzaghi, Frederique,Webb, Robert R.,Beeley, Nigel R.A.
, p. 1467 - 1470 (2007/10/03)
We report on the synthesis, biological evaluation and structure-activity relationships for a series of 3-benzazepine derivatives as 5-HT2C receptor agonists. The compounds were evaluated in functional assays measuring [3H] phosphoinositol turnover in HEK-293 cells transiently transfected with h5-HT2C, h5-HT2A or h5-HT2B receptors. Several compounds are shown to be potent and selective 5-HT 2C receptor agonists, which decrease food intake in a rat feeding model.